NCT00006053View on ClinicalTrials.gov

STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2000

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Leukemia
Interventions
DRUG

imatinib mesylate

Trial Locations (1)

07936

Novartis Pharmaceuticals Corporation, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY